Together, CARMELINA® and CAROLINA® constitute a comprehensive CV outcomes trial programme

A robust CVOT programme assessing the long-term safety profile of linagliptin in a broad range of patients

Click on the logos below or use the tabs at the top of the page to learn more about each trial

CV, cardiovascular; CKD, chronic kidney disease; HbA1c, glycated haemoglobin; T2D, type 2 diabetes
1. Rosenstock J et al. JAMA 2019;321:69; 2. Marx N et al. Diab Vasc Dis Res 2015;12:164; 3. Boehringer Ingelheim. Press release. 2019. http://www.boehringer-ingelheim.com/press-release/CAROLINA-top-line (accessed March 2019)

For more details

Visit the CAROLINA® page for information on the trial design, endpoints, patient population and topline announcement

Click here to access the page

Visit the CARMELINA® page for information on the trial design, endpoints, patient population, results and implications

Click here to access the page

Visit the resources page for links to publications and other resources for both trials

Click here to access the page

©2019 Boehringer Ingelheim International GmbH. All rights reserved.